OEM News, People

Turing Medical Taps ex-iRhythm CEO Kevin King as Chief Exec

Under King’s leadership, Turing plans to launch a clinical trial of its pioneering PACE therapy for treatment resistant depression.

Author Image

By: Sam Brusco

Associate Editor

Kevin King. Photo: LinkedIn.

Turing Medical, a company specializing in precision brain mapping and targeting technologies, has named former iRhythm Technologies CEO Kevin King as its new president and CEO.

As president and CEO of iRhythm, King guided the company from early-stage startup through a successful public offering. Before iRhythm, he was CEO of Affymetrix, now part of Thermo Fisher Scientific, and Thomson Reuters Healthcare.

King also had a number of senior executive positions in MRI at GE HealthCare. He began his career in HP’s Medical Products Group.

“Turing Medical is poised to revolutionize neuroscience and bring hope to millions suffering from devastating neuropsychiatric disorders,” said King. “The innovative technology developed by Nico Dosenbach and Damien Fair represents the culmination of their lifelong scientific mission. I’m profoundly inspired to help translate their visionary work into transformative therapies that will fundamentally change how we treat brain disorders—potentially restoring lives once thought irrevocably altered by disease.”

The company is developing advanced, functional connectivity MRI processing techniques that can generate detailed, personalized circuit maps to help understand and treat brain disorders. Under King’s leadership, Turing plans to launch a clinical trial of its pioneering PACE (Personalized Adaptive Cortical Electro-stimulation) therapy for treatment resistant depression.

The approach combines the Bullsai platform’s targeting capabilities with a novel, minimally invasive neuromodulation therapy to offer sustainable relief for patients who haven’t responded to conventional treatments.

Turing received U.S. Food and Drug Administration (FDA) 510(k) clearance for Bullsai—an automated, cloud-based system that delivers individual brain maps to support neurosurgical planning—in September 2024.

“Bringing Kevin King on as CEO marks a defining moment for Turing,” said Nico Dosenbach, co-founder of Turing Medical. “As CEO of iRhythm, Kevin built one of the most successful digital health companies of our time—changing the standard of care for millions living with heart conditions. His track record of turning bold ideas into widely adopted clinical solutions makes him the ideal leader to help Turing redefine how we treat serious brain disorders.”

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters